Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFalpha Monoclonal Antibody, Administered Intravenously, in Subjects With Active Psoriatic Arthritis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 01 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Nov 2022 Post Hoc analysis (n=241) evaluating the minimal disease activity (MDA) of golimumab, presented at the ACR Convergence 2022.
21 Mar 2022 Results of pooled analysis assessing safety of three studies (NCT00973479, NCT02181673 & NCT02186873) published in the Arthritis Research and Therapy.
01 Sep 2021 Results of a post-hoc analysis assessing long-term effects of golimumab on patient-reported outcome measures to determine HRQoL through 1 year in patients with active PsA published in the Clinical Rheumatology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com